Christopher Emig

Dr. Christopher Emig

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Arnaud GermainArnaud Germain
Arnaud Germain
JJJillian R. Jaycox
Jillian R. Jaycox
CEChristopher Emig
Christopher Emig
ARAaron M. Ring
Aaron M. Ring
MHMaureen R Hanson
Maureen R Hanson
Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a debilitating disorder characterized by serious physical and cognitive impairments. Recent research underscores the role of immune dysfunction, including the role of autoantibodies, in ME/CFS pathophysiology. Expanding on previous studies, we analyzed 7542 antibody–antigen interactions in ME/CFS patients using two advanced platforms: a 1134 autoantibody Luminex panel from Oncimmune and Augmenta Bioworks, along with Rapid Extracellular Antigen Profiling (REAP), a validated high-throughput method that measures autoantibody reactivity against 6183 extracellular human proteins and 225 human viral pathogen proteins. Unlike earlier reports, our analysis of 172 participants revealed no significant differences in autoantibody reactivities between ME/CFS patients and controls, including against GPCRs such as β-adrenergic receptors. However, subtle trends in autoantibody ratios between male and female ME/CFS subgroups, along with patterns of herpesvirus reactivation, suggest the need for broader and more detailed exploration.

13 June 2022 in Proteomes
Verified
Journal Article
Open access
PDF file
AOAdam James O'Neal
Adam James O'Neal
KGKatherine Anne Glass
Katherine Anne Glass
CEChristopher Emig
Christopher Emig
AVAdela A. Vitug
Adela A. Vitug
SHSteven J. Henry
Steven J. Henry
MHMaureen R Hanson
Maureen R Hanson
Infectious pathogens are implicated in the etiology of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) because of the occurrence of outbreaks of the disease. While a number of different infectious agents have been associated with the onset of ME/CFS, the identity of a specific organism has been difficult to determine in individual cases. The aim of our study is to survey ME/CFS subjects for evidence of an infectious trigger and/or evidence of immune dysregulation via serological testing of plasma samples for antibodies to 122 different pathogen antigens. Immune profiles were compared to age-, sex-, and BMI-matched controls to provide a basis for comparison. Antibody levels to individual antigens surveyed in this study do not implicate any one of the pathogens in ME/CFS, nor do they rule out common pathogens that frequently infect the US population. However, our results revealed sex-based differences in steady-state humoral immunity, both within the ME/CFS cohort and when compared to trends seen in the healthy control cohort.

13 October 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
CEChristopher Emig
Christopher Emig
MMMarco A. Mena
Marco A. Mena
SHSteven J. Henry
Steven J. Henry
AVAdela Vitug
Adela Vitug
CVChristian John Ventura
Christian John Ventura
DCDale J. Christensen
Dale J. Christensen
Infections from the SARS-CoV-2 virus have killed over 4.6 million people since it began spreading through human populations in late 2019. In order to develop a therapeutic or prophylactic antibody to help mitigate the effects of the pandemic, a human monoclonal antibody (mAb) that binds to the SARS-CoV-2 spike protein was isolated from a convalescent patient following recovery from COVID-19 disease. This mAb, designated AUG-3387, demonstrates a high affinity for the spike protein of the original viral strains and all variants tested to date. In vitro pseudovirus neutralization and SARS-CoV-2 neutralization activity has been demonstrated in vitro. In addition, a dry powder formulation has been prepared using a Thin-Film Freezing (TFF) process that exhibited a fine particle fraction (FPF) of 50.95 ± 7.69% and a mass median aerodynamic diameter (MMAD) and geometric standard deviation (GSD) of 3.74 ± 0.73 µm and 2.73 ± 0.20, respectively. The dry powder is suitable for delivery directly to the lungs of infected patients using a dry powder inhaler device. Importantly, AUG-3387, administered as a liquid by intraperitoneal injection or the dry powder formulation delivered intratracheally into Syrian hamsters 24 hours after intranasal SARS-CoV-2 infection, demonstrated a dose-dependent reduction in the lung viral load of the virus. These data suggest that AUG-3387 formulated as a dry powder demonstrates potential to treat COVID-19.

25 October 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
CEChristopher Emig
Christopher Emig
AVAdela Anne Vitug
Adela Anne Vitug
CXADR is a membrane protein present in epithelial tight junctions and other tissues with a variety of known functions, in addition to its role as entry receptor for coxsackie B virus and adenovirus 2 and 5. We identified a previously unknown function of CXADR as a binding partner for human IgG but not IgA, IgE, IgM, or ScFv in a non paratope specific manner. Binding was specific to human and rabbit IgG, and not observed for mouse, rat, donkey, or goat IgG. Binding of Ig to CXADR is inhibited by FcBlock (BD), and is competitive with anti-Fc binding secondary antibodies, but not anti-Fab secondary antibodies, indicating that CXADR binds the Fc portion of IgG. CXADR, being a member of the immune superfamily of proteins, has similar structural homology to other Ig binding proteins, including Fc receptors. We conclude that CXADR has a previously unknown function as a human Fc receptor, serving as a direct link between the humoral adaptive immune system and many cell types in the human body previously unknown to express FcR.

8 October 2026 in medRxiv
Verified
Preprint
Open access
PDF file
JMJohn MacMahon
John MacMahon
CEChristopher Emig
Christopher Emig
PHPrue H Hart
Prue H Hart
BWBenjamin Wang
Benjamin Wang
Richard WellerRichard Weller
Richard Weller
ASAndrew Stevenson
Andrew Stevenson
OBJECTIVE To assess associations of ambient UV with cardiovascular and cancer mortality across US Health Service Areas (HSAs), prioritise outcomes by signal and attributable burden, assess racial and ethnic variation, with UK Biobank corroboration. DESIGN Ecological analysis of HSAs using linear regression of crude mortality on ambient UV and social vulnerability, with correction for multiple comparisons. SETTING US HSAs and UK Biobank. DATA SOURCES Publicly available US data and UK Biobank data accessed under Application 82526. PARTICIPANTS 704 808 annual cardiovascular deaths (aged ≥65) and 565 287 annual cancer deaths (aged ≥50) from populations of 52.8 and 115.2 million; UK Biobank analyses included 412 665 individuals. MAIN OUTCOME MEASURES Cardiovascular, all-cancer, and body-site-specific cancer mortality; regression slope per interquartile-range increase in UV (β UV/IQR), modelled attributable burden for US data, and hazard ratios for the UK Biobank data. RESULTS Higher UV was associated with lower cardiovascular (βUV/IQR −68.3 deaths/100 000; P<0.001) and all-cancer mortality (−43.2; P<0.001), corresponding to 36 043 (5.1%) and 49 789 (8.8%) fewer US deaths annually, respectively. Associations varied by race and ethnicity. Cardiovascular findings were directionally consistent between US and UK datasets. All-cancer mortality and 10 of 18 cancers were inversely associated with UV in the US; UK analyses found inverse associations for all-cancer and two individual body-site-specific cancers. Twelve cancers showed directionally concordant associations across the datasets, of which ten were inverse. Lung cancer showed the strongest inverse association in each dataset. CONCLUSIONS Higher UV was associated with lower cardiovascular and cancer mortality across US HSAs, with modelled attributable burdens exceeding 5%; UK Biobank findings provided partial corroboration. Twelve of 18 site-specific cancers were directionally concordant between datasets. US race-stratified heterogeneity did not follow a skin-colour gradient, suggesting residual confounding.